{"organizations": [], "uuid": "e547f61335a778ce0460288f033fb5c3083cc977", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180328.html", "section_title": "Archive News &amp; Video for Wednesday, 28 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-cyclacel-pharmaceuticals-posts-qtr/brief-cyclacel-pharmaceuticals-posts-qtrly-loss-of-2-1-mln-idUSASC09U25", "country": "US", "domain_rank": 408, "title": "BRIEF-Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.457, "site_type": "news", "published": "2018-03-29T04:15:00.000+03:00", "replies_count": 0, "uuid": "e547f61335a778ce0460288f033fb5c3083cc977"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-cyclacel-pharmaceuticals-posts-qtr/brief-cyclacel-pharmaceuticals-posts-qtrly-loss-of-2-1-mln-idUSASC09U25", "ord_in_thread": 0, "title": "BRIEF-Cyclacel Pharmaceuticals Posts Qtrly Loss Of $2.1 Mln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "cyclacel pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28 (Reuters) - Cyclacel Pharmaceuticals Inc:\n* CYCLACEL PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS\n* CYCLACEL PHARMACEUTICALS - ‍AS OF DEC 31, 2017, CASH AND CASH EQUIVALENTS TOTALED $23.9 MILLION, COMPARED TO $16.5 MILLION LAST YEAR\n* CYCLACEL PHARMACEUTICALS INC - NET LOSS APPLICABLE TO COMMON SHAREHOLDERS FOR THREE MONTHS ENDED DEC 31, 2017 WAS $2.1 MILLION​ Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-03-29T04:15:00.000+03:00", "crawled": "2018-03-29T15:55:54.123+03:00", "highlightTitle": ""}